The USPTO has granted a patent to Vistagen’s non-opioid oral product candidate AV-101 for neuropathic pain treatment.

Today we meet Craig. He suffered from neuropathy for 5-7 years. He feared the walker and wheelchair. His balance was very ...

Neuropathy, a debilitating condition affecting millions worldwide, can significantly impair daily life and well-being.

Neuropathy, a condition that affects individuals of all ages but is most common in older adults, often causes pain in the ...

NeuFit is revolutionizing neurological rehabilitation with its innovative approach that integrates advanced diagnostics and ...

If the attention generated by BioSpace’s coverage of this landmark approval is any indication, Americans are hungry for ...

Explore how chemotherapy causes peripheral neuropathy in 40% of cancer patients. Learn about the risk factors and the need ...

Four in every 10 cancer patients treated with chemotherapy develop severe peripheral nerve pain, a new review suggests.

Our friends with Essential Neuropathy break down what Neuropathy actually is and how they can pinpoint the problem and find ...

Worldwide, cancer chemotherapy is linked to persistent severe peripheral nerve pain (neuropathy) for around 4 in every 10 patients treated with these drugs, suggests a pooled data analysis of the ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has ...

The US Food and Drug Administration (FDA) has approved Vertex Pharmaceuticals’ oral Journavx (suzetrigine) to treat adults ...